Stock LYRA LYRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.3255 USD -0.18% Intraday chart for Lyra Therapeutics, Inc. -15.01% -93.79%
May. 21 Lyra Therapeutics Reduces Workforce to Extend Cash Runway MT
May. 21 Lyra Therapeutics, Inc. Announces Cost-Cutting Measures to Preserve Capital CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lyra Therapeutics Reduces Workforce to Extend Cash Runway
MT
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
AQ
Lyra Therapeutics, Inc. Announces Cost-Cutting Measures to Preserve Capital
CI
Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50
MT
HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy
MT
Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell
MT
Lyra Therapeutics Lead Drug Candidate Fails in Phase 3 Study
DJ
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
AQ
Lyra Therapeutics, Inc. Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
CI
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Lyra Therapeutics, Inc. Announces Board Changes
CI
Lyra Therapeutics Files $300 Million Mixed Shelf Offering
MT
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics to Participate in Upcoming Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LYRA Stock
  4. News Lyra Therapeutics, Inc.